Since October 7, 2023, Lebanon has experienced an alarming escalation in attacks on health care, with nearly half of these assaults proving fatal to health workers or patients. As of November 21, 2024, 47% of the 137 recorded attacks in…
Population Health Research Institute (PHRI), a joint initiative of McMaster University and Hamilton Health Sciences, is celebrating its 25th anniversary as a global leader in health research. Over the past quarter-century, PHRI has made transformative contributions to patient care worldwide…
NorthStar Medical Radioisotopes, LLC, a leader in radiopharmaceutical innovation, has entered into a strategic Master Supply Agreement with Cellectar Biosciences, Inc. (NASDAQ: CLRB). Under the agreement, Cellectar will integrate NorthStar’s high-purity, non-carrier-added (n.c.a.) Actinium-225 (Ac-225) into its proprietary Phospholipid Ether…
Trinity Life Sciences, a leader in strategy, insights, and analytics for the life sciences industry, has introduced a groundbreaking approach to evaluating the impact of Field Medical Affairs in its new white paper, Measuring the Impact of Field Medical Affairs.…
Pfizer Inc. (NYSE: PFE) has received marketing authorization from the European Commission (EC) for HYMPAVZI™ (marstacimab) for the routine prevention of bleeding episodes in patients aged 12 years and older, weighing at least 35 kg, with severe hemophilia A (congenital…
On Wednesday, November 20, the UN Climate Conference (COP29) in Baku, Azerbaijan, spotlighted urbanization and transportation as critical areas for climate action. The day emphasized the pivotal role of cities and towns in reducing global emissions and advancing public health.…
CVS Health is the first healthcare company to receive Health Equity accreditation from URAC, recognizing the work done through CVS Caremark and CVS Specialty. URAC sets high standards in healthcare quality, covering clinical practice, consumer protections, performance measurement, operations infrastructure,…
Novartis has secured the top spot in the 2024 Access to Medicine Index (ATMI), highlighting the company’s leadership in enhancing global access to medicines. The Access to Medicine Index, published biennially, is an independent report that evaluates the efforts of…
Merck (NYSE: MRK), known as MSD outside the U.S. and Canada, today announced positive topline results from the pivotal Phase 3 MK-3475A-D77 trial, which assessed the noninferiority of subcutaneous pembrolizumab, Merck’s anti-PD-1 therapy, combined with chemotherapy, versus intravenous (IV) KEYTRUDA…
Celltrion presented new findings from Phase III randomized controlled trials (RCTs) for its biosimilar candidates CT-P41 (referencing PROLIA®/XGEVA® for postmenopausal osteoporosis) and CT-P47 (referencing ACTEMRA® for moderate-to-severe rheumatoid arthritis) at the American College of Rheumatology (ACR) Convergence 2024 in Washington,…
As world leaders gather in Rio de Janeiro, Brazil, for the G20 Summit this weekend, the city’s iconic Christ the Redeemer statue will be bathed in teal light in a symbolic show of support for the global fight against cervical…
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Adult Patients With Unresectable Non-Epithelioid Malignant Pleural Mesothelioma (MPM) Merck (NYSE: MRK), known as MSD outside the U.S. and Canada, announced that the European Medicines Agency’s…